Tom Brady Just Took a C‑Suite Job at a $2 Billion Company in the GLP‑1 Weight‑Loss Race

The NFL star has joined eMed as chief wellness officer, as the GLP-1 platform eyes a $2 billion valuation and a shot at transforming employer healthcare.

BY AMAYA NICHOLE, NEWS WRITER

Tom Brady. Illustration: Inc.; Photos: Getty Images; Adobe Stock

As the market for GLP-1 weight-loss drugs surges toward a projection of over $100 billion, retired NFL quarterback Tom Brady is stepping into the arena.

The seven-time Super Bowl champion and Linda Yaccarino, CEO of eMed—a Miami-based, AI-powered digital healthcare platform—recently joined forces to announce that Brady will serve as the company’s chief wellness officer.

Brady said he’s looking forward to helping people in the new role. “Trying to share the things I’ve learned from incredible mentors…that have helped me kind of live my dream, and I want to do that for others,” said Brady in an interview with Fox News.

“He’s very involved in the company, sitting alongside me at meetings with CEOs, grinding and sharing … he shares the same core values when it comes to population health.” Yaccarino told Axios.

How Anthropic's Claude AI Became a Co-Founder

Founded in 2020, eMed initially supplied at-home Covid-19 tests. Recently, it pivoted to weight loss and provides GLP-1 medications and chronic weight management care programs related to obesity and type 2 diabetes.

The company made headlines last year when it named Yaccarino, the former head of X as its CEO and appointed Amy Elkins, X’s former global head of strategic partnerships, as the COO.

In addition to adding Brady to its leadership team, the company reported a $200 million funding round, valuing the digital health company at more than $2 billion.

© Inc.com